84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00926627April 200922/6/2009Safety and Efficacy Study of Bosentan in Progressive Pulmonary SarcoidosisA Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary SarcoidosisSarcoidosis;Pulmonary HypertensionDrug: bosentan;Drug: placeboDaniel DobererNULLTerminated18 Years70 YearsBoth32Phase 2Austria
2EUCTR2007-005117-18-AT03/04/200804/03/2008Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACSafety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC Progressive pulmonary sarcoidosis
MedDRA version: 9.1Level: PTClassification code 10037430Term: Pulmonary sarcoidosis
Trade Name: Tracleer
Product Name: Bosentan
Medical University of Vienna, Department of Clinical PharmacologyNULLNot RecruitingFemale: yes
Male: yes
Austria
3NCT00581607April 200826/12/2007Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionDouble Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary Arterial HypertensionDrug: Bosentan;Drug: PlaceboUniversity of CincinnatiActelionCompleted18 YearsN/ABoth43Phase 2/Phase 3United States
4EUCTR2006-005361-19-GB09/03/200717/12/2006Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosisEvaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms.
MedDRA version: 8.1 Level: LLT Classification code 10037400 Term: Pulmonary hypertension
St Georges HospitalNULLNot Recruiting Female: yes
Male: yes
45 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): yesUnited Kingdom